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Abstract: Alpha-1 antitrypsin (A1AT) is a 52 kDa serine protease inhibitor that is synthesized 
in and secreted from the liver. Although it is present in all tissues in the body the present con-
sensus is that its main role is to inhibit neutrophil elastase in the lung. A1AT deﬁ ciency occurs 
due to mutations of the A1AT gene that reduce serum A1AT levels to 35% of normal. The 
most clinically signiﬁ cant form of A1AT deﬁ ciency is caused by the Z mutation (Glu342Lys). 
ZA1AT polymerises in the endoplasmic reticulum of liver cells and the resulting accumulation 
of the mutant protein can lead to liver disease, while the reduction in circulating A1AT can 
result in lung disease including early onset emphysema. There is currently no available treatment 
for the liver disease other than transplantation and therapies for the lung manifestations of the 
disease remain limited. Gene therapy is an evolving ﬁ eld which may be of use as a treatment 
for A1AT deﬁ ciency. As the liver disease associated with A1AT deﬁ ciency may represent a 
gain of function possible gene therapies for this condition include the use of ribozymes, peptide 
nucleic acids (PNAs) and RNA interference (RNAi), which by decreasing the amount of aber-
rant protein in cells may impact on the pathogenesis of the condition.
Keywords: alpha-1 antitrypsin deﬁ ciency, siRNA, peptide nucleic acid, ribozymes
Introduction
Alpha-1 antitrypsin (A1AT) is an acute phase 52kDa 418 amino acid glycoprotein that 
is primarily synthesized and secreted by the hepatocytes in the liver1 though it is also 
actively transcribed and secreted in smaller amounts by cells including neutrophils, 
mononuclear phagocytes, enterocytes,2 and human respiratory epithelial cells.3
It is present in all tissues of the body with its primary role being to inhibit the 
enzyme neutrophil elastase (NE).4 It also inhibits to a much lesser degree; trypsin, 
chymotrypsin, cathepsin G, plasmin, thrombin, tissue kallikrein, factor Xa, plasmino-
gen and proteinase 3.5
A1AT has other pathobiologically relevant functions in addition to elastase inhibi-
tion. There is a direct pro-survival effect of A1AT through inhibition of lung alveolar 
endothelial cell apoptosis. Primary pulmonary endothelial cells internalize human 
A1AT which co-localizes with and inhibits staurosporine-induced caspase-3 activa-
tion. A1AT is among several serum proteins that can rescue serum withdrawal-induced 
apoptosis.6 Inhibition of structural alveolar cell apoptosis by A1AT represents a novel 
protective mechanism of this serpin against emphysema.6
A1AT has also been reported to play an immunoregulatory role, to inhibit neutro-
phil superoxide production, to induce the release of macrophage-derived interleukin-1 
(IL-1) receptor agonist, and to increase hepatocyte growth factor production in human 
lung ﬁ broblasts in vitro. In vivo A1AT has been shown to protect against tumor necro-
sis factor-α (TNFα) or endotoxin-induced lethality and in a mouse model of lung 
inﬂ ammation and connective tissue breakdown it was shown that A1AT binds to the 
secreted enteropathogenic Escherichia coli proteins EspB and EspD thereby reducing 
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their hemolysis of red blood cells. Thus A1AT may not only 
afford protection against proteolytic injury, but may also have 
the potential to neutralize microbial activities and to exert 
effects on the regulation of innate immunity. In this regard 
there is growing evidence that A1AT is also able to inhibit 
lipopolysaccharides (LPS)-induced inﬂ ammatory responses 
in vitro and in vivo.7
A1AT is a member of the serine proteinase inhibitor 
(Serpin) family of proteins. This family also includes α-1 
antichymotrypsin, α-2 antiplasmin, plasminogen activator I, 
thyroxine-binding globulin and angiotensin, among others. 
Serpins are single chain proteins containing a conserved 
domain structure of 370–390 residues, usually ﬂ anked by 
amino or carboxyl terminal extensions. The serpins exist in 
a metastable state and their energy is released by cleavage of 
their reactive centre. A target protease binds to and cleaves 
the reactive centre of the serpin which then transposes the 
protease to the other end of the serpin molecule. In the pro-
cess the protease is crushed against the serpin, with a loss of 
structural integrity that ensures its destruction.8
A crucial factor in the destruction is the strength of the 
bond between serpin and protease.8 Inhibitory serpins inter-
act with their target proteinase at the reactive site which is 
located within a loop structure 30–40 amino acids from the 
carboxyl terminus.9
The speciﬁ city of a serpin for its protease is determined by 
the side chain of the amino acid in the reactive centre of the 
serpin. The mature A1AT protein consists of a single chain 
of amino acids with three N-asparaginyl-linked complex 
carbohydrate side chains.5 As already stated the target protein 
of A1AT is NE. A1AT has a methionine at its reactive centre 
which enables it to inhibit NE as NE cleaves at methionyl 
residues.8 The predominant feature of cleaved, inactive ser-
pins is the presence of an anti-parallel six-stranded β-sheet 
(the A sheet) in which the central strand contains several 
residues upstream from the cleavage site.9
With 80 million neutrophils from the pulmonary arterial 
circulation travelling through human lungs every second, 
the pulmonary parenchymal stroma is exposed to an array 
of proteolytic enzymes including proteinase-3, cathespin G 
and NE. Of these NE is thought to be the most important in 
the development of pulmonary emphysema. It is a 29 kDa, 
220 amino acid, single chain polypeptide glycoprotein 
synthesized in promyelocytes and packaged in neutrophil 
azurophilic granules. NE is released in large quantities in 
response to neutrophil activation10 and is one of the few 
human enzymes capable of cleaving insoluble, cross-linked 
elastin which modulates the elastic recoil of tissues, including 
the alveolar walls of the lower respiratory tract.5 After an 
inﬂ ammatory event, in normal circumstances, the NE is 
inhibited and controlled by A1AT.
Genetics of A1AT defi ciency
The A1AT gene is located on the q arm of chromosome 14 
at position 14q32.1.11,12 It is a 12.2-kilobase pair gene com-
posed of seven exons and six introns. The protein is encoded 
by the protease inhibitor (Pi) locus. The Pi locus is highly 
polymorphic, resulting in different A1AT isotypes that can 
be detected by electrophoresis.13
There are many normal A1AT alleles, and at least four 
common ‘M’ alleles. The many different alleles can be either 
normal, null (express no A1AT), dysfunctional (non-functional 
A1AT is expressed in the serum) or deﬁ cient (serum A1AT 
levels 35% of normal). More than 100 different allelic 
variations of A1AT have been described. Over 95% of the 
population has one of the four M alleles.14
The numerous A1AT phenotypes are named according 
to their migration characteristics in a pH4 to pH5 isoelectric 
focusing (IEF) polyacrylamide gel. Variants displaying a 
higher isoelectric point are conferred with letters from the 
beginning of the alphabet whereas those with lower isoelec-
tric points are named from the end of the alphabet.10 When 
two alleles have an identical IEF pattern and the sequence 
difference is known, the relevant residue is speciﬁ cally indi-
cated. For example; the two most common A1AT alleles, 
M1 (Val213) and M1 (Ala213), have IEF patterns of M1, but 
differ at residue 213 by the neutral amino acids Val and Ala. 
Some rare alleles are labeled by a letter indicating the IEF 
position together with the birth site of the allele (M
procida
). 
The null alleles are labeled “null” together with the place of 
origin (Null
bellingham
).5
One in 10 people of European descent are carriers of 
one of the two most common base-substitution mutations 
of A1AT that result in its deﬁ ciency. The more common is 
the S mutation (Glu264Val). In homozygotes this results in 
a 40% decrease in plasma A1AT concentrations. The most 
clinically signiﬁ cant mutation is the Z allele (Glu342Lys). 
Approximately 4% of Northern Europeans and 3% of people 
in the United Sates are heterozygous for the Z allele (PiMZ), 
with approximately 1 in 2000 being homozygotes (PiZZ). 
Homozygosity for the Z allele reduces plasma levels of 
A1AT to 10%–15% of normal. In PiZZ homozygotes, or 
those that co-inherit the Z allele and the S mutation plasma 
concentrations of A1AT will be insufﬁ cient to ensure lifetime 
protection of the lungs from proteolytic damage, particularly 
in smokers.8
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More than 90% of clinical cases of A1AT deﬁ ciency are 
caused by the PiZZ mutation. This occurs at an allelic fre-
quency of 0.01 to 0.02 in North American white persons and 
0.02 to 0.03 in Northern Europeans. The allelic frequency is 
lower in Southern Europeans (0.009) and African Americans 
(0.004). This demographic distribution also refers to the 
rarer clinically signiﬁ cant alleles. The null allele occurs 
with an allelic frequency of 0.00017. The reason for the 
predominance of the Z allele is unknown, but does raise the 
possibility that heterozygosity confers a survival advantage 
on the host.10
Gene-mapping studies show that the PiZ allele probably 
arose in northern Europe and age estimates of the A1AT 
variants suggest that it ﬁ rst appeared 107 to 135 generations 
ago and could have been spread in Neolithic times. The 
PiS deﬁ ciency allele is older. It is estimated to have arisen 
279–470 generations ago and from its high incidence on the 
Iberia peninsula it has been suggested that PiS could have 
arisen in this region.15
A study of genetic epidemiologic studies from peer-
reviewed literature was used to establish the worldwide racial 
and ethnic distribution of A1AT deﬁ ciency. The database 
estimated that the deﬁ ciencies would be present in a variety 
of populations and races.16 A study of 96 Filipino infants with 
a history of jaundice since two weeks old, however; found an 
extremely low incidence of A1AT deﬁ ciency with only one 
patient positive for the PiS allele and negative for the periodic 
acid-Schiff (PAS) positive hepatic globules characteristic of 
the deﬁ ciency.17 A similar study of 58 children with either 
chronic liver disease or neonatal cholestasis syndrome was 
carried out in India. None of the children had A1AT-deﬁ cient 
phenotypes.18
Low plasma concentrations are also associated with two 
other rare variants of A1AT, S
iiyama
 (Ser53Phe) and M
malton
 
(ΔPhe52), the commonest causes of A1AT deﬁ ciency in 
Japan and Sardinia, respectively.8 S
iiyama
 is also associated 
with PAS-positive, diastase-resistant inclusion bodies in 
the liver. The serine at position 53 is thought to contribute 
to the organization of the internal core element of the A1AT 
molecule. The deﬁ cient state in S
iiyama
 may therefore be due 
to the change from an uncharged polar to a nonpolar amino 
imposed on the conserved serpin backbone which may exert 
severe effects on the integrity of the molecule and hence alter 
the intracellular processing of A1AT.19
ZA1AT is the mutation which causes the most severe and 
most clinically relevant form of A1AT deﬁ ciency. The Z muta-
tion (Glu342Lys) in A1AT occurs at the head of the ﬁ fth 
strand of the A-sheet and affects the mobility of the reactive 
centre loop and therefore the physical properties of A1AT. 
The mutation results in a unique molecular interaction 
Table 1 The A1AT alleles and their effects
Allele Genetic change Serum A1AT levels μM 
(Less than 11 = defi cient)
Effects
M Normal Homozygous (MM): 20–48 Normal
S Glu246Val Homozygous (SS): 15–33
 • Mild plasma defi ciency 
 • Not clinically signifi cant usually 
 • No hepatocellular aggregation
Z Glu342Lys Heterozygous (MZ): 12–35 Heterozygous (SZ): 
8–19 Homozygous (ZZ): 2.5–7
Carrier 
Defi cient 
Most signifi cant defi ciency 
 •  Associated with emphysema and liver disease
 •  Intra-hepatocellular polymerisation key feature
Siiyana Ser53Phe  • Severe plasma defi ciency 
 • I ntra-hepatocellular polymerisation
Mmalton ΔPhe52  • Severe plasma defi ciency 
 •  Intra-hepatocellular polymerization
 •  Next to Z allele, most frequently associated with 
liver disease
I Arg39Cys
 • Rare 
 • Mild plasma defi ciency 
 •  Intra-hepatocellular polymerisation
Null Homozygous: 0
 • Complete plasma defi ciency 
 • No polymerization 
 • Not associated with liver disease
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between the reactive centre loop of one molecule and the 
gap in the A-sheet of another. This process can continue 
until large polymers form. This loop-sheet polymerisation 
of Z antitrypsin occurs spontaneously at 37 °C.20
The loop-sheet polymerization has provided an excellent 
explanation for the aggregation of the Z-variant of A1AT 
in the liver endoplasmic reticulum (ER). The polymers of 
ZA1AT form aggregates. These aggregates are present as 
diastase-resistant PAS positive inclusions of A1AT in the 
ER of periportal cells. These inclusions result in a deﬁ ciency 
of circulation plasma A1AT, reducing plasma levels of the 
protein to 10%–15% of normal.21
Electron microscopy of the hepatocytic inclusions in 
PiZZ homozygotes reveals bead-like necklaces of A1AT 
polymers. These polymers are resistant to the usual degrada-
tive processes of the ER because the individual molecules 
retain their ordered structure and hence fail to elicit the 
chaperone binding needed to activate degradation.8 The 
oligosaccharide structure of the accumulated material from 
the PAS-positive diastase-resistant inclusions is compatible 
with a blockage of processing prior to entry to the Golgi. 
The protein accumulation occurs after core glycosylation 
in the endoplasmic reticulum but before the high mannose 
pruning which takes place in the Golgi. On extraction from 
the inclusions the A1AT is functionally active although 
this ZA1AT had only 15% of the activity of MA1AT.22 
The Z mutation reduces the association rate between A1AT 
and NE by approximately ﬁ vefold.20 Therefore not only is 
there less A1AT in PiZZ individuals, but the population of 
ZA1AT molecules is less competent as an inhibitor of NE 
than MA1AT, and this suggests that PiZZ individuals have 
far less functional antielastase protection than the reduced 
concentration of A1AT alone would imply.23
Polymerization of A1AT and consequent globular deposits 
are enhanced by high temperatures. Storage is speeded up also 
by the increase in synthesis of A1AT because polymerization 
is a concentration-dependent phenomenon. Consequently 
hepatocytic storage accelerates during febrile illness and 
infectious diseases (the acute-phase response) that involve 
either the liver or other organs. In fact in these conditions 
A1AT synthesis is incremental as the body temperature rises.24 
A1AT is an acute-phase reactant as its plasma levels increase 
during the host response to inﬂ ammation/tissue injury.25 It 
should be noted however that differing results have been 
reported regarding the effects of temperature on the secre-
tion/polymerization of ZA1AT and it is unlikely that there is 
a simple relationship between febrile episodes and phenotypic 
expression of liver disease in A1AT-deﬁ cient patients.
The process of intra-hepatic polymerization also underlies 
the mild plasma deﬁ ciency of the common S (Glu264Val) 
and rare I (Arg39Cys) alleles of antitrypsin and the severe 
plasma deﬁ ciency of the S
iiyama
 and M
malton
 alleles.26
There is a strong genotype-phenotype correlation in these 
diseases that can be explained by the molecular instability 
caused by the mutation and, in particular, the rate at which 
the mutant forms polymers. Those mutants that cause the 
most rapid polymerisation cause the most retention of 
A1AT within the liver. This correlates with the greatest risk 
of liver damage and cirrhosis, and the most severe plasma 
deﬁ ciency.27
There is prolonged hepatic retention of the A1AT Saar 
allele even though this allele does not have polymerogenic 
properties. The retention of this allele in the ER may be even 
more prolonged than that of ZA1AT even though A1AT 
Saar does not form insoluble polymers. This indicates that 
there could be mechanisms other than polymerization that 
determine whether mutant A1AT molecules are retained in 
the ER. It also raises the question of whether the polymer-
ization of ZA1AT is the cause or the result of ER retention 
of the protein.25,28
Clinical manifestations of A1AT 
defi ciency in the lung
A1AT deﬁ ciency was ﬁ rst described by Laurell and Erikkson 
in 1963,29 and it is associated with a substantially increased 
risk for the development of pulmonary emphysema by the 
4th or 5th decade of life.20 It is thought that the emphysema 
is caused by the lack of fully active A1AT in the pulmo-
nary interstitium which results in the unopposed action of 
proteases, the gradual destruction of pulmonary connective 
tissues and the loss of alveolar units.10 It appears that patients 
with lower rates of secretion and low plasma A1AT levels 
risk rapid development of emphysema whereas those with 
somewhat higher rates of synthesis have better protection 
of alveolar tissue.
Cigarette smoking markedly accelerates the develop-
ment of emphysema in individuals with A1AT deﬁ ciency. 
This can be explained in part because the key Met358 in the 
active site of A1AT can be easily oxidized. When oxida-
tion occurs the association rate constant of A1AT for NE is 
reduced 2000-fold. Cigarette smoke and inﬂ ammatory cells 
in the lower respiratory tract can oxidize the Met efﬁ ciently.5 
Studies from this laboratory have demonstrated that in addi-
tion to Met358, Met351 is also susceptible to oxidation and site-
directed mutants of A1AT with alanines substituted for these 
key methionines are resistant to oxidative inactivation.30
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Major differences in pathology exist between emphysema 
in PiMM and PiZZ individuals. This is due to the proteolytic 
attack and tissue destruction present in A1AT deﬁ ciency, and 
the fact that in its native form ZA1AT is ﬁ vefold less efﬁ -
cient at inhibiting neutrophil elastase than normal MA1AT. 
A1AT is also locally produced on the epithelial surface of 
the lung. This ZA1AT polymerises at body temperature and 
is both an ineffective antiprotease inhibitor and a neutrophil 
chemoattractant.31 There is already an excess of neutrophils 
in the airways of individuals suffering from ZA1AT-related 
emphysema and the polymers cause an inﬂ ux of neutro-
phils. The excess of neutrophils is likely due to elevated 
pro-inﬂ ammatory cytokines such as IL-8 and leukotriene 
B4. The clearance of the A1AT polymers is impaired as 
they are bound to the alveolar wall. This enables them to 
act as a chronic stimulus for neutrophil inﬂ ux into ZA1AT 
lungs. Thus the single amino acid substitution converts an 
anti-inﬂ ammatory molecule into a pro-inﬂ ammatory stimulus 
and this contributes in part to the excessive inﬂ ammation 
that underlies the progressive emphysema associated with 
ZA1AT deﬁ ciency.32
Bronchial secretions of chronic obstructive pulmonary 
disease (COPD) patients with A1AT deficiency were 
observed to have increased levels of IL-8 and, in particular 
leukotriene B
4
 (LTB
4
). LTB
4
 and IL-8 are both potent che-
motactic agents capable of promoting neutrophil transendo-
thelial migration. The absolute contribution of LTB
4
 and IL-8 
was signiﬁ cantly higher in the sputum from patients with 
A1AT deﬁ ciency than in patients without A1AT deﬁ ciency, 
although the remaining sputum chemotactic activity (not 
accounted for by LTB
4
 or IL-8) did not differ signiﬁ cantly 
between the two groups.33 A possible explanation for the 
presence of these two chemoattractants in the sputum is 
the presence of free elastase as elastase has been shown to 
stimulate LTB
4
 release from alveolar macrophages as the 
macrophages bind uninhibited NE due to the presence of 
surface receptors for NE.34
Sputum inﬂ ammation and chemotactic activity can be 
inﬂ uenced by variations in patient characteristics such as the 
degree of lung function impairment, the presence of acute 
exacerbations, cigarette smoking, corticosteroid treatment 
and high bacterial load.33
Clinical manifestations of A1AT 
defi ciency in the liver
A1AT deﬁ ciency is also associated with liver disease. The 
PiZ and PiM
malton
 mutations are those most frequently asso-
ciated with liver disease. Sharp and colleagues (1969) ﬁ rst 
described cirrhosis in A1AT deﬁ ciency in 10 children from 
six families and later reported the characteristic intrahepa-
tocyte PAS diastase-resistant inclusions.35
Of PiZ adults who have been systematically followed, it 
appears that ∼50% die at a mean age of 52 yr of severe lung 
disease. Those subjects have mild or no signs of liver disease. 
Mortality of the remaining 50% occurs ∼10 yr later with signs 
of chronic progressive liver disease at death and milder lung 
disease. Among PiMZ heterozygotes, lung disease is not sig-
niﬁ cantly increased but chronic progressive liver disease has 
been found occasionally with progression to cirrhosis and, 
rarely, hepatoma. A German study looking at liver carcinoma 
and tumor-bearing tissue found that there is an increased risk 
of primary liver carcinoma among PiZ heterozygotes and 
that PiZ-associated carcinoma may develop in noncirrhotic 
tissue.36 However a more recent study in Florida found that 
there was no association between the PiMZ state and chronic 
liver disease in general, but among patients with liver disease 
there was a signiﬁ cantly higher number of PiMZ patients 
suffering from severe liver disease compared to those suf-
fering with less severe liver disease. It was also discovered 
that there was a signiﬁ cant association between the PiMZ 
heterozygous state and the increased severity of liver disease 
and the need for transplantation in patients with hepatitis C 
virus (HCV). These represent interim results of a long-term 
study into the role of heterozygous A1AT deﬁ ciency in 
chronic liver disease 37
While homozygous inheritance of the Z deﬁ ciency allele 
is associated with an increased risk for both emphysema and 
liver disease, the homozygous inheritance of a null allele is 
associated with a higher risk of emphysema but no risk of liver 
disease.5 Patients with a higher rate of synthesis of ZA1AT 
tend to have a greater prevalence of liver disease than patients 
who have a low rate of expression. These second group tend 
towards emphysema. A1AT deﬁ ciency is the most common 
genetic cause of liver disease in children and predisposes adults 
to chronic liver disease and hepatocellular carcinoma.25
Large scale screening for A1AT deﬁ ciency in Sweden 
between 1972 and 1974 showed that of 200,000 neonates 
there were 120 PiZZ individuals, only 14 of whom had pro-
longed jaundice with nine developing severe liver disease. 
In addition two PiZ-, 54 PiSZ and one PiS- children were 
identiﬁ ed.38
The consistent occurrence of overt liver disease in new-
born infants, in contrast to its only occasional occurrence in 
young adults, may be explained by the fact that the liver cells 
in the infants are less capable of degrading the polymerized 
protein.8
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While the intrahepatocytic globules of A1AT are nontoxic 
in themselves, being present in all PiZ individuals including 
those who never develop liver disease, the accumulation 
does hamper the natural defenses of hepatocytes through an 
engorgement of the cellular synthetic pathway. This leads to a 
toxic gain-of-function. The accumulated ZA1AT is subjected 
to degradation by the ER-associated degradation pathway 
(ERAD).39 The proteasome also plays an important role in the 
ER degradation of ZA1AT in many cell types.40 Autophagy 
represents a nonproteasomal mechanism by which the pro-
tein is degraded.41 Where the protein is not degraded at a 
high enough rate the ER stress response is activated. The 
three main functional components of the ER stress response 
are the ER overload response (EOR), the unfolded protein 
response (UPR) and apoptosis.14 Endoplasmic reticulum 
stress responses have evolved to be protective, however when 
they are ineffective, toxic damage occurs demonstrating how 
these responses can be described as a double edged sword.42 
Interestingly human hereditary chromatosis, a genetic liver 
disease associated with iron overload is also characterized 
by ER stress.43
This derangement of cellular functions renders hepato-
cytes more prone to damage by external insults which can 
have particularly damaging effects on the neonatal liver due 
to its relatively immature structure and function.24 In early 
childhood, the most common presentation of A1AT deﬁ cien-
cy’s effect on the liver is prolonged jaundice. Abnormal liver 
function is largely self-limiting, but it can sometimes persist 
into adolescence. It is estimated that 5%–10% of A1AT 
deﬁ cient patients over the age of 50 will develop cirrhosis. 
A study examining adult patients with A1AT deﬁ ciency and 
chronic liver disease revealed a late onset of symptomatic 
hepatic abnormalities. Sixty eight percent of the patients 
studied were 60 years or older when the liver disease was 
discovered. There seemed to be a later onset of the liver 
disease in the heterozygotes. At the time of diagnosis, the 
hepatic condition usually was advanced.44
The liver damage occurs through a gain-of-function 
mechanism, unlike the lung disease, which is due to loss-
of-function. The retention of the mutant ZA1AT molecules 
in the ER triggers a series of events that are eventually hepa-
totoxic.45 This gain-of-function mechanism is illustrated in 
ZA1AT transgenic mice. The liver disease is apparent in the 
mice even though normal levels of antielastases expressed by 
endogenous genes are still present, therefore the liver injury 
can not be attributed to loss of function.46
The variability in the severity of liver disease and the age of 
onset among patients with A1AT deﬁ ciency may be explained 
in part by individual variations in episodes of inﬂ ammation and 
hence to increased synthesis of A1AT.8 A study that involved 
the transfection of human skin ﬁ broblasts with ZA1AT from 
patients with and without liver disease found that there was a 
marked delay in the degradation of the accumulated protein 
in the cells from those subjects with liver disease, compared 
to those without liver disease. Human skin ﬁ broblasts do not 
express the endogenous A1AT gene, but presumably express 
genes involved in the processing of secretory proteins. This 
result would suggest that there are other genetic traits that 
affect the fate of the ZA1AT molecule within cells.45 Virus-
induced liver disease in deﬁ cient subjects frequently assumes 
a chronic course because of the deranged immunologic system 
of these subjects. Studies have demonstrated that PiZ subjects 
with liver disease have anomalies of immunomodulation and 
anomalous activation of the complement cascade.24
Cirrhosis is favored over restitution as the proteases 
released by leukocytes during the inﬂ ammatory response 
to the hepatocytic necrosis cannot be properly counteracted 
and collagen and reticulum ﬁ bers are improperly rearranged 
during the healing process. Increased numbers of collagen 
bundles have been observed in the space of Disse and 
around hepatocytes in A1AT-deﬁ cient patients. An insuf-
ﬁ cient defense against reactive oxygen metabolites has been 
hypothesized to perpetuate the liver damage.24
The accumulation of ZA1AT can cause liver damage 
in transgenic PiZZ mice where the degree of liver damage 
correlates with the amount of ZA1AT accumulated in the 
liver of the different pedigrees of mice. Although 40% of 
the PiZZ mice tested were seropositive for mouse hepatitis 
virus (MHV), comparison of the PiZZ mice with and without 
MHV showed no difference in liver damage. The degree 
of liver damage was therefore not inﬂ uenced by the MHV 
seropositivity; rather, it was related only to the presence of 
accumulated ZA1AT protein.46
Male gender and obesity have been found to predispose 
A1AT deﬁ cient individuals to liver disease.47 The associa-
tion of the hepatitis virus with A1AT deﬁ ciency is less clear. 
An Austrian study of A1AT deﬁ cient patients with chronic 
liver disease found that 62% of those with cirrhosis were 
HCV positive and 33% showed evidence of hepatitis B virus 
(HBV) infection.48 Another study found that the odds of hav-
ing a heterozygous Z phenotype increased in patients with 
HCV compared to a control population, where patients with 
hepatitis C or B virus were 3.6 times more likely to have a 
heterozygous Z phenotype than a normal phenotype.49
Some studies, however; have found no association 
between hepatitis C infection and A1AT deficiency.50 
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A study into the PiMZ population found that the prevalence 
of A1AT PiMZ was no greater in hepatitis C patients than 
in the general population.51
The nonsteroidal anti-inﬂ ammatory drug (NSAID) indo-
methacin causes an increase of liver damage in transgenic 
ZA1AT expressing mice. It is estimated that NSAIDs are used 
by 15–0 million people in the United States on a long-term 
basis. The administration of indomethacin increases hepatic 
injury as indicated by the increase in hepatocellular prolif-
eration and increased activation of caspase-9. Indomethacin-
induced injury is associated with activation of IL-6-STAT3 
signaling, increased expression of A1AT mRNA and greater 
accumulation of polymerized ZA1AT in the liver. This indi-
cates that environmental factors such as exogenous medication 
administration can signiﬁ cantly potentiate the liver injury 
associated with ZA1AT hepatic accumulation; NSAIDs may 
be especially injurious to patients with A1AT deﬁ ciency, 
possibly by increasing the expression and accumulation of  the 
hepatotoxic mutant protein.52 As the Z mutation may lead to 
worse liver injury in the setting of other liver diseases inter-
play of cholestasis and the PiZZ phenotype was investigated 
in transgenic mice. A bile duct ligation (BDL) was carried 
out on mice possessing a transgenic alpha1-ATZ mutation 
and littermate controls. PiZ transgenic mice undergoing BDL 
developed more liver ﬁ brosis than wild-type mice after BDL. 
Increased apoptosis was also noted in PiZ BDL mice.53 This 
shows that PiZ transgenic mice are more susceptible to liver 
ﬁ brosis induced by cholestasis from BDL. The Z mutation of 
A1AT may act as a modiﬁ er gene in patients with concurrent 
liver diseases such as cystic ﬁ brosis and cholestasis. Similarly 
the co-existence of the Z mutation and C282Y HFE (the pro-
tein involved in human hereditary hemochromatosis) act as 
potential disease modiﬁ ers with respect to each other in terms 
of expression on ER stress responses.43
PiZZ subjects with liver disease are prone to develop a 
hepatocellular type of carcinoma. Mild or severe hepatocytic 
dysplasia is not an infrequent sign found in biopsy specimens. 
Usually liver cancer develops in a patient with cirrhosis or 
other chronic liver disease. Occasionally however, PiZZ 
patients with hepatocellular carcinoma do not have cirrhosis. 
Usually globules are situated in the periportal hepatocytes, 
but in the cirrhotic nodules they are spread throughout.24
A1AT deﬁ ciency may also affect other human pro-
teins. A recent case report involved a patient presenting 
with polycythemia (a known paraneopaetic manifestation 
of hepatoma which requires the presence of alpha-fetopro 
[AFP]) but with normal serum levels of AFP. This patient 
was found to have A1AT deﬁ ciency. Infants with neonatal 
hepatitis and A1AT deﬁ ciency do not have raised AFP. It was 
postulated that this is because A1AT is a rate limiting factor 
in the production of AFP. The authors raised the possibility 
of A1AT deﬁ ciency resulting in normal AFP in adults with 
hepatocellular carcinoma.54
Overall 10% of PiZZ neonates develop hepatitis and cho-
lestasis. Cholestasis usually occurs in the ﬁ rst two months, 
though it may persist for up to eight months.55 In early child-
hood patients may present with jaundice in which the stools 
generally contain no yellow or green pigment, indicating 
cholestasis and mimicking biliary atresia. All patients have 
hepatomegaly and about 50% also have splenomegaly. 
Approximately 5% of the patients present with an increased 
bleeding tendency. This is due to vitamin K deﬁ ciency caused 
by the cholestasis-induced malabsorption. Less commonly 
children present later in childhood with hepatosplenomegaly 
or with cirrhosis.13
Current therapeutics
The only corrective therapy for A1AT deﬁ cient patients with 
severe liver disease currently is liver transplantation. The 
most recent study shows that the 1-, 3-, and 5-year patient 
survival is 89%, 85%, and 83%, respectively, for adults after 
transplantation versus 92%, 90%, and 90% for pediatric 
patients after transplantation.56 In cases where transplanta-
tion is not possible there are palliative beneﬁ ts of portocaval 
shunting. The beneﬁ cial effects of both breast feeding and 
vitamin E supplementation in cholestatic infants have been 
suggested.10
In 2003 the American Thoracic Society published their 
ﬁ rst new set of guidelines for the management of obstructive 
lung disease associated with A1AT deﬁ ciency since 1989. 
They recommended standard treatments as per nonhereditary 
emphysema.
Augmentation therapy has been given for the treatment 
of lung disease associated with A1AT deﬁ ciency since 1987. 
The levels of A1AT in serum, bronchoalveolar lavage ﬂ uid 
and the pulmonary interstitium, required to provide protec-
tion against proteolytic lung destruction, have been estimated 
from those observed in PiSZ persons who have lower than 
normal levels of A1AT but no demonstrable increase in 
premature lung disease. These levels can be reached and 
maintained in PiZZ and null individuals by intermittent 
infusions of plasma-puriﬁ ed A1AT.10
Gene therapeutics
As emphasized by the ATS in 2003 there is no therapy 
available other than liver transplantation for individuals with 
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advanced A1AT-deﬁ ciency liver disease. To address this 
challenge there have been a number of investigations into 
alternative methods to treat the liver disease. As the adverse 
effects of A1AT deﬁ ciency are due to the expression of a 
single gene, the speciﬁ c knockdown of this gene has high 
potential for the treatment of the deﬁ ciency. Gene therapy 
may be a possibility for treatment of the liver disease. Gene 
therapy was originally designed as a means to provide thera-
peutic merit by introducing genetic material (DNA or RNA) 
encoding a protein that is missing or defective into a patient’s 
cells or tissues. Newer gene therapy approaches aimed at 
inhibiting the expression of a target mutant gene include 
RNA interference (RNAi) mediated through small interfering 
RNA (siRNA), peptide nucleic acids, and ribozymes. These 
approaches can be used to stop the production of the mutant 
Z protein, hence stopping the accumulation of the protein in 
the liver and providing protection against liver disease.
A recent study investigated the effects of small DNA 
fragments (SDFs) on A1AT. This is the DNA technology of 
small fragment homologous replacement (SFHR) which is 
versatile in that sequences can be directly altered, inserted or 
deleted. Treatment involves direct conversion of the mutant 
sequence to a wild-type genotype, thereby restoring the 
normal phenotype. Small DNA fragments are introduced into 
the cell and recombine with the genomic DNA at a targeted 
site, thereby producing a speciﬁ c change in the sequence. 
SDFs including normal M and ZA1AT sequences were gen-
erated and transfected into peripheral blood monocytes from 
PiM subjects and PiZ subjects. The defective gene could be 
corrected in ZA1AT monocytes in vitro with SDFs, and treat-
ment was associated with an increase in A1AT secretion. The 
development of this methodology to repair the gene defect 
in hepatocytes could have beneﬁ cial effects on secretion, 
thereby protecting both the lung and liver.57
RNAi and siRNA
Post-transcriptional gene silencing (PTGS) was ﬁ rst observed 
in petunias at the end of the 1980s. Attempts to enhance the 
hue of petals via the introduction of a chimeric gene unex-
pectedly resulted in the production of completely white petals 
with corresponding knockdown in mRNA levels. The devel-
opmental timing of mRNA expression of the endogenous 
gene was not altered by introduction of an exogenous gene, 
but the level of the mRNA produced by the endogenous gene 
was seen to decrease 50-fold from wild-type levels. Somatic 
reversion of plants with white ﬂ owers to phenotypically 
parental violet ﬂ owers was associated with a coordinate rise 
in the steady state levels of the mRNAs produced by both the 
endogenous and introduced genes.58 This led to the discovery 
of RNA interference (RNAi).
RNA interference (RNAi) is the evolutionary-conserved 
process of sequence-speciﬁ c, post-transcriptional gene silencing 
in animals and plants, initiated by double-stranded RNA 
(dsRNA) that is homologous in sequence to the silenced gene.59 
RNAi is exclusively found in eukaryotes. This is because in pro-
karyotes RNase III, which is a very potent and fast ds-speciﬁ c 
RNase, degrades dsRNA substrates as short as 12 bp.60
Although the pathway of RNAi is under constant investi-
gation, many of the underlying mechanisms have been clari-
ﬁ ed. The process is divided into distinct steps. The initiation 
of post transcriptional gene silencing occurs on processing 
of a dsRNA by an enzyme known as Dicer into ∼22nt guide 
sequences. These guide sequences are known as small 
interfering RNA (siRNA). The siRNA then forms part of 
a multi-component nuclease, the RNA-induced silencing 
complex (RISC), and instructs it to destroy speciﬁ c mRNAs.61 
Fractionation indicates that RISC and the process generating 
siRNAs from dsRNA are separate, though the two enzymes 
responsible may interact at some point during the silencing 
process. RNA III family members are among the few nucle-
ases that show speciﬁ city for dsRNA.62 Dicer is evolutionary 
conserved in worms, ﬂ ies, plants, fungi, and mammals.63
In actively proliferating cells siRNA activity lasts for up 
to 1 week, whereas in terminally differentiated cells such 
as neurons, the silencing can last for up to 3 weeks.64 This 
transiency is due to the fact that mammalian cells lack the 
RNA-dependent RNA polymerases that amplify siRNAs in 
nonmammalian cells such as Caenorhabditis elegans. As 
a result the siRNA duplexes become progressively diluted 
as cells divide.65 This could be an ideal therapeutic window 
for many chronic diseases, for although it would necessitate 
repeat administrations of siRNA every few weeks this would 
be a short enough term to lessen concerns regarding the long-
term toxicity of permanently silencing a gene, while still a 
long enough treatment time to be a worthwhile therapy.66 This 
would be particularly useful for the liver disease associated 
with A1AT deﬁ ciency.
The delivery in vivo of siRNAs by liposomes has proven 
successful. The complexation of a siRNA targeting the Bcl-2 
oncogene with liposomes resulted in the successful inhibi-
tion of tumor formation in mice.67 Liposomes were also used 
to demonstrate that RNAi can be used successfully in vivo 
to signiﬁ cantly reduce functional expression of the V
2
R in 
the mouse kidney.68 Liposomes have been used in vivo in 
a number of studies in mouse models and may represent a 
potential method to deliver siRNA successfully.
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The delivery in vivo of siRNAs by cationic lipids has 
been described. Other strategies for local or systemic siRNA 
administration have been explored including chemical modi-
ﬁ cations of siRNA molecules, electropulsation, polyamine or 
other basic complexes, atelocollagen, virosomes and certain 
protein preparations.
In addition it is also possible to target siRNAs to speciﬁ c 
organs including the liver. This can prevent unwanted effects on 
normal host tissues. Targeted delivery can be achieved by local 
administration or by injection via catheterization of the vascular 
supply to particular organs. Chemically modiﬁ ed siRNA could 
possibly also be covalently linked to ligands for cell-surface 
receptors, enabling delivery only to cells bearing these recep-
tors.66 The delivery of siRNA into model mammalian organisms 
has been achieved by intravenous injection or by electroporation 
of synthetic siRNAs directly into target tissues and organs.69 In 
rodents the rapid infusion of siRNA by hydrodynamic injection 
has seen successful transgene delivery in the liver with expres-
sion found in up to 40% of hepatocytes.70
Cruz and colleagues reported successful knockdown 
of A1AT in cell lines using A1AT siRNAs.71 They also 
successfully knocked down the expression of ZA1AT in 
ZA1AT overexpressing transgenic mice.
Pulmonary disease in A1AT deﬁ ciency is due to low serum 
levels of A1AT. Knockdown of ZA1AT expression would be 
of no beneﬁ t here, as it would further reduce the serum levels 
of circulating A1AT. As a gene therapy alternative to augmen-
tations therapy the normal A1AT gene has been successfully 
introduced into the striated muscle cells of animals using an 
AAV vector both in vitro and in vivo.72,73 A1AT gene replace-
ment therapy may be of beneﬁ t to the pulmonary disease as 
the A1AT administered is in the form of MA1AT and trials 
are ongoing. ZA1AT knockdown and MA1AT replacement 
together could potentially be a very effective way of treating 
A1AT deﬁ ciency in PiZZ individuals. The major challenges to 
this therapy will include targeted delivery and chronicity.
Peptide nucleic acids
Although peptide nucleic acids were originally conceived 
as agents for double-stranded DNA binding, they were ﬁ rst 
exploited for gene therapy drug design. PNAs were ﬁ rst 
described by Nielson et al in 1991.74 They are synthetic DNA 
dsRNA
siRNA
RISC
siRNA unwinds and associates with RISC
Cleavage occurs within siRNA sequence
Dicer
Activated RISC
Cleaved mRNA
Target 
mRNA
Figure 1 Mechanism of RNA interference. dsRNA are processed by Dicer to produce siRNA of 21–23 nucleotides in length.  The dsRNA unwinds, allowing one strand to blind 
to the RNA-induced silencing complex (RISC). Binding of the antisense RNA strand activates the RISC to cleave mRNAs containing a homologous sequence. 
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analogs in which the phosphodiester backbone has been 
replaced by repetitive units of the pseudo-peptide polymer 
N-(2-aminoethyl) glycine to which the purine and pyrimi-
dine bases are attached by a methyl carbonyl linker.75 PNAs 
hybridize to complementary DNA or RNA in a sequence-
dependent manner, according to the Watson–Crick hydrogen 
bonding scheme. In contrast to DNA, PNA can bind in either 
a parallel or antiparallel manner.76 The inhibition of gene 
expression by PNA is known as anti-gene inhibition when it 
occurs as a result of PNA binding to DNA, and as antisense 
inhibition when it occurs as a result of PNA binding to 
RNA. The synthetic uncharged peptide backbone provides 
PNA with unique hybridization characteristics. There is no 
electrostatic repulsion when PNAs hybridize to their target 
nucleic acid sequence and this gives a higher stability to the 
PNA–DNA or PNA–RNA duplexes than the natural homo- or 
heteroduplexes.77 PNAs are also not degraded by nucleases or 
proteases and; therefore, cannot be directly used as primers, 
or be copied.75
PNAs can form strand invasion complexes or result in 
strand displacement in DNA and thus lead to the inhibition 
of gene transcription. Several in vitro studies have shown 
that the binding of PNA or bis-PNA to complementary DNA 
can efﬁ ciently block transcriptional elongation and inhibit 
the binding of transcriptional factors.
The interaction of PNAs with mRNA is independent of 
the RNA secondary structure. The antisense effects of PNAs 
occur through the steric interference of RNA processing 
or transport into cytoplasm or through the interference of 
translation. This interference is caused by the binding of PNA 
to the mRNA. The antisense inhibition caused by siRNAs is 
due to RNase mediated degradation; however, PNAs are not 
substrates for RNase.78
PNAs could constitute highly efﬁ cient compounds for gene 
therapy as the oligomers have good stability and a strong bind-
ing afﬁ nity for DNA and RNA. They are also non-toxic, even 
at relatively high concentrations. However, as with siRNA, 
progress in the use of PNAs as tools for regulating gene expres-
sion slows at the in vivo stage. This is due to the slow uptake of 
naked PNA by living cells. Modiﬁ cations of PNAs have led to 
signiﬁ cant improvements in the uptake of PNA in eukaryotic 
cells. PNAs can be coupled to DNA oligomers, to receptor 
ligands or more efﬁ ciently to peptides such as cell penetrating 
peptides which are rapidly internalized by mammalian cells.79 
Such coupling markedly improves the uptake of PNAs by cells. 
As with siRNA liposomes can be of use to improve the uptake 
of PNAs when PNAs are incorporated into the liposomes.80
Ribozymes
Another method of inhibiting the expression of a gene is 
through the use of ribozymes. Ribozymes are naturally 
occurring catalytic RNA molecules that cleave RNA with 
high speciﬁ city. They behave like enzymes though there is 
no protein involved. The catalytic properties of RNA were 
discovered in the 1980s by Thomas Cech and Sidney Altman 
and the term ‘ribozyme’ was coined in 1982.81
Many ribozymes have either a hammerhead or hairpin 
shaped active center. Synthetically designed and speciﬁ cally 
targeted hammerhead and hairpin ribozymes have been shown 
to be promising gene-targeting reagents. These ribozymes con-
tain both a catalytic RNA domain that cleaves the target mRNA 
and a substrate-binding domain with a sequence antisense to 
the target mRNA sequence. Therefore, these gene-targeting 
ribozymes bind to the mRNA sequence through Watson–Crick 
interactions between the target sequence and the antisense 
sequence in the substrate-binding domain of the ribozyme.82
Ribozymes bind to their targets with a much higher 
speciﬁ city than siRNAs, which can potentially produce off-
target effects. There is no risk of an interferon response with 
ribozymes, unlike with siRNA. As with siRNA and PNAs 
there are problems using ribozymes to knockdown gene 
expression in vivo. The activity in vivo is not usually high 
enough to achieve the desired effects.
Human hepatoma cells were transduced with ribozymes to 
inhibit the expression of the mutant A1AT gene and express 
DNA
DNA
DNA + PNA
RNA + PNA Protein
TranslationTranscription
Transcription
Anti-gene inhibition
Anti-sense inhibition
RNA
Figure 2 PNA-induced gene inhibition. PNA can bind with DNA leading to anti-gene 
inhibition, or it can bind with RNA leading to antisence inhition.
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a modiﬁ ed A1AT gene. This ribozyme-mediated gene therapy 
did show inhibition of the mutant gene and expression of the 
modiﬁ ed A1AT gene; however the efﬁ ciency of this method 
is low. 83
Perspective
Gene therapy has been under investigation since the emer-
gence of restriction enzymes. Retroviral vectors were inves-
tigated and the ﬁ rst human trials began in the late 1980s.84 
Gene therapy with recombinant adenovirus (rAd) has since 
developed and recombinant adenovirus (rAAV) trials were 
carried out in cystic ﬁ brosis (CF) patients in 1993.85 Recombi-
nant adeno-associated virus trials were initiated in CF patients 
in 1995.86 Lentivirus and recombinant herpesvirus vectors 
have also been used. rAd, rAAV, lentivirus and recombinant 
herpesvirus vectors are capable of gene transfer and expres-
sion in vivo in nondividing cells.87 Non-viral gene transfer 
methods include DNA conjugates, and naked DNA injection 
and these came into use in gene therapy in the 1990s.
There are drawbacks to all of these methods of gene 
therapy. Wild-type Ad triggers innate and acquired immune 
responses. Recombinant Ad also triggers these responses in 
a dose-dependent manner. Gamma-retrovirus vectors have 
caused leukemia-like syndromes when used on bone-marrow 
stem cells. Recombinant AAV vectors can generate adaptive 
immune responses to the retained viral capsid proteins. Aero-
sol administration of nonviral vectors has been associated 
with an inﬂ uenza-like syndrome and the efﬁ cacy of theses 
systems in vivo is low and transient.
The only indications of clinically signiﬁ cant efﬁ cacy with 
gene therapy have been with onco-retrovirus vectors and a 
ﬁ rst-generation rAd vector, but these systems are associated 
with important limiting toxicities.
Gene therapy targeted to the liver has also been attempted. 
A study into the effectiveness of adenoviral delivery of 
interferon alpha to rats that were induced to develop human 
hepatocellular carcinoma and liver cirrhosis found that 
targeting of IFN-alpha expression to the liver signiﬁ cantly 
reduced liver tumor volume and ameliorated liver cirrhosis.88 
In addition pseudotyped AAV vectors for the liver-speciﬁ c 
expression of human blood coagulation factor IX (hFIX) 
have been investigated and expression in immunocompe-
tent mice ranged from 36% to more than 2000% of normal. 
Expression was dose- and time-dependent.89 With respect 
to gene-targeted therapeutics for liver disease in general the 
efﬁ cacy of novel strategies still needs to be further validated 
in animal studies and conﬁ rmed in clinical trials. Particularly 
important are their efﬁ cient and safe delivery to the target 
tissue and the limitation of unintended harmful nonspeciﬁ c 
effects such as transient or sustained inﬂ ammation.
siRNA, PNA and Ribozymes represent potential gene 
knockdown methods and with the ongoing investigation 
into their administration in vivo remains only a matter of 
time until a valid gene therapy emerges. For A1AT-deﬁ cient 
individuals this development would be most welcome. The 
liver disease caused by the polymerization of ZA1AT and the 
inﬂ ammatory effects due to the chemotactic characteristics 
of polymerized ZA1AT in the lung could both potentially be 
ameliorated by the knockdown of ZA1AT gene and protein 
expression in these organs. With the continuing investiga-
tions into A1AT augmentation therapy the adverse effects of 
A1AT deﬁ ciency may soon be completely overcome.
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